ReachMD CME

CME credits: 1.00 Valid until: 16-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/managing-egfr-mutated-mnsclc-data-recommendations/56306/ Over the past two decades, advances in disease biology and precision medicine have transformed the diagnosis and treatment of non–small cell lung cancer (NSCLC). Improved understanding of NSCLC molecular drivers has led to the development of t...

CME credits: 0.25 Valid until: 15-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/mechanism-to-match-choosing-the-right-vmat2-strategy-for-the-patient/54717/ This Podcast Plus discussion reviews how treatment for tardive dyskinesia can be individualized based on patient-specific goals and pharmacologic considerations. The program examines clinically relevant differences among VMA...

CME credits: 0.25 Valid until: 14-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/no-patient-with-ckd-left-behind-new-horizons-in-patients-with-ckd-regardless-of-diabetes-status/49260/ A growing body of evidence presented at ERA 2026 is reshaping the conversation around chronic kidney disease management, regardless of diabetes status. In this expert interview, Dr. Katherine Tuttl...

CME credits: 1.00 Valid until: 13-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/moving-beyond-sleep-the-broader-connection-between-the-orexin-system-and-psychiatric-disorders/48749/ Sleep and psychiatric disorders are often managed separately in clinical practice, leaving key biological mechanisms unaddressed and contributing to recurrent cycles of relapse. Overlapping factors,...

CME credits: 0.25 Valid until: 13-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-outcomes-in-patients-with-fsgs-a-case-based-approach-in-the-new-era-of-targeted-therapy/35906/ Focal segmental glomerulosclerosis (FSGS) remains a challenging disease, with many patients progressing to kidney failure and experiencing substantial effects on quality of life. As the treatmen...

CME credits: 0.25 Valid until: 09-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-incorporating-novel-treatment-options-for-schizophrenia-into-clinical-practice-overcoming-clinical-inertia/54751/ Although dopamine D₂ receptor antagonists have long been the standard treatment for schizophrenia, many patients experience inadequate symptom control or adverse...

CME credits: 1.00 Valid until: 07-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/precision-through-the-continuum-applying-biomarker-guided-therapies-in-ovarian-cancer/56953/ This chapterized online educational activity is designed to translate biomarker-driven evidence into practical decision-making across the ovarian cancer continuum. Through expert discussion, participants wil...

CME credits: 1.00 Valid until: 06-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/beyond-igf-1r-il-6r-inhibition-and-future-sequencing/60946/ Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emergi...

CME credits: 1.00 Valid until: 06-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/comparing-trial-designs-outcomes-across-igf-1r-therapies/60945/ Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how em...

CME credits: 1.00 Valid until: 06-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/understanding-igf-1r-inhibition-mechanism-clinical-implications/60944/ Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See...

CME credits: 1.00 Valid until: 06-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/designing-efficient-clinic-workflows-for-ted-therapy-access/60943/ Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how...

CME credits: 1.00 Valid until: 06-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/overcoming-real-world-barriers-to-ted-treatment/60942/ Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TE...

CME credits: 1.00 Valid until: 06-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/why-qol-measures-change-ted-management/60941/ Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapi...

CME credits: 1.00 Valid until: 06-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/applying-cas-eugogo-visa-a-micro-case/60940/ Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapie...

CME credits: 1.00 Valid until: 06-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/why-staging-ted-correctly-matters-even-when-cas-is-low/60939/ Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emer...

CME credits: 0.25 Valid until: 30-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/The-Future-of-mCSPC-Molecular-Profiling-and-Biomarker-Directed-Therapies/56688/ This podcast explores the evolving role of molecular profiling and biomarker testing in metastatic castration-sensitive prostate cancer (mCSPC). Drs. Neeraj Agarwal and Rana McKay discuss the clinical significance of PTE...

CME credits: 0.25 Valid until: 30-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/Cracking-the-Code-in-Localized-nmCSPC-Risk-Treatment-and-Timing/56686/ In this podcast, Drs. Rana McKay and Neeraj Agarwal discuss risk stratification in localized and nonmetastatic castration-sensitive prostate cancer (CSPC), highlighting the clinical and imaging factors used to identify patients a...

CME credits: 0.25 Valid until: 24-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/screening-workup-hypercortisolism-resistant-hypertension/50076/ With our current understanding of how prevalent hypercortisolism is in patients with difficult-to-manage cardiometabolic disease, the focus shifts to what might clinicians do differently in practice? Which patients should healthcare pro...

CME credits: 0.50 Valid until: 23-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/reimagining-alzheimers-care-the-advent-of-subcutaneous-administration-of-anti-amyloid-therapy/39878/ In this activity, Dr. Alireza Atri and Dr. Scott Turner discuss the evolving role of subcutaneous anti-amyloid monoclonal antibody therapy in early Alzheimer disease. The conversation compares intrav...

CME credits: 0.25 Valid until: 23-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/translating-evidence-into-action-nonsteroidal-mras-in-patients-with-hf/49259/ In this panel discussion from the ESC Heart Failure Congress 2026, Drs. Muthu Vaduganathan, Michael Böhm, and Koichiro Kinugawa discuss the role of nonsteroidal MRAs in patients with HFmrEF and HFpEF. Using a clinical case...

CME credits: 0.25 Valid until: 18-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/engaging-adult-patients-with-c3gn-shared-decision-making-at-the-crossroads-of-complement-targeted-therapy/54145/ In this Patient-Clinician Connection, Dr. Sayna Norouzi discusses shared decision-making approaches for adult patients with C3 glomerulonephritis (C3GN) receiving complement-targeted ther...

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/De-Novo-mHSPC-Recognizing-the-Patients-Who-Need-More/57195/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and em...

CME credits: 0.25 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/aace-guidance-hypercortisolism-adults-diabetes/50073/ Updated diabetes guidelines now recognize a new “other” category of diabetes linked to excess cortisol. This classification reflects emerging prevalence data showing that hypercortisolism may play a much larger role in diabetes development than p...

CME credits: 0.75 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/unblocking-clinical-inertia-the-cmi-era-in-ohcm-care/56382/ Did you miss our symposium at ESC HF 2026? It’s not too late! This CME-accredited broadcast replay focuses on improving the diagnosis and management of obstructive hypertrophic cardiomyopathy (oHCM). Learn how to distinguish oHCM from heart...

CME credits: 0.25 Valid until: 15-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/simple-diagnostic-steps-that-change-td-outcomes-increase-quality-of-life/54716/ This Podcast Plus discussion outlines standardized approaches to identifying and managing tardive dyskinesia. It reviews routine screening practices, use of tools such as AIMS, and key symptoms and timing in at-risk pati...